stockrow
Friday 6 November 2026
Export PRPH’s income statement to Excel — free account
ProPhase Labs, Inc.
PRPH Healthcare Diagnostics & Research
ProPhase Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 35.8% from fiscal 2024.
- Revenue
- −18.9%
- EPS
- +80.0%
- Free cash flow
- +56.7%
- Total debt
- +19.4%
Quarter to June 2026, against a year earlier
0.01
0.00
0.00%
Follow PRPH
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.76 | 2.29 | 0.33 | 0.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.46) | (8.09) | (1.48) | (16.17) | |
P/B ratio |
2.77 | 2.84 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.06 | 3.60 | 2.04 | 2.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.93) | (1.88) | (1.21) | (1.25) | |
EV/FCF |
(1.95) | (1.90) | (1.23) | (1.25) | |
Quick Ratio |
0.07 | 0.03 | 0.03 | 0.03 | |
Current Ratio |
0.14 | 0.06 | 0.06 | 0.05 | |
Net Debt/EBITDA |
(0.55) | (4.26) | (4.99) | (6.13) | |
Debt/Assets |
2.92% | 9.68% | 9.97% | 9.88% | |
Debt/Equity |
0.28 | 1.65 | (9.54) | (1.82) | |
Asset Turnover |
0.06 | 0.07 | 0.06 | 0.06 | |
Operating CF/Net income |
0.51 | 0.17 | 0.14 | 0.03 | |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | 0.00 | |
Interest Coverage |
(3.08) | (1.34) | (4.00) | (3.34) | |
Research and Development Expense of Revenue |
0.68% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
524.92% | 761.86% | 579.92% | 283.98% | |
Intangible Assets out of Total Assets |
0.18 | 0.19 | 0.18 | 0.17 | |
Share Based Compensation of Revenue |
48.81% | 55.23% | 81.59% | 37.09% | |
Graham Net Nets |
(2.68) | (5.35) | (50.73) | (45.76) | |
Graham Number |
0.00 | 0.00 | 1.97 | 3.59 | |
Earnings Yield |
(391.50%) | (429.89%) | (3,849.44%) | (2,871.67%) | |
Free Cash Flow Yield |
(55.46%) | (82.63%) | (508.06%) | (438.39%) | |
Revenue per Share |
0.21 | 0.04 | 0.04 | 0.07 | |
Operating CF per Share |
(0.84) | (0.06) | (0.06) | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.84) | (0.06) | (0.06) | (0.01) | |
Cash per Share |
0.10 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
1.65 | 0.16 | (0.05) | (0.22) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.65 | 0.16 | (0.05) | (0.22) | |
Free Cash Flow |
(3.49) | (1.23) | (0.74) | (0.08) | |
Working Capital |
(47.51) | (49.93) | (52.99) | (55.28) | |
Capital Expenditures |
0.00 | 0.00 | 0.01 | 0.00 | |
Net Current Asset Value |
(51.07) | (53.21) | (56.23) | (57.72) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | (0.03) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
17.46 | 10.80 | 10.87 | 10.81 | |
Average Payables |
28.65 | 27.14 | 27.53 | 29.20 | |
Average Inventory |
2.12 | 0.61 | 0.61 | 0.45 | |
Average Assets |
78.76 | 61.54 | 54.42 | 49.73 | |
Average Common Equity |
22.49 | 5.43 | 7.25 | 4.16 |
Columns are period end dates · fundamentals updated 26 Oct 2026